A statement released earlier today by Commerzbank AG about Fresenius (ETR:FRE) bumps the target price to 81.00EUR
- Updated: January 11, 2017
Commerzbank AG bumped up the target of Fresenius (ETR:FRE) to 81.00EUR stating a potential upside of 0.11%.
On 1/10/2017, Independent Research GmbH released a statement for Fresenius (ETR:FRE) bumped up the target price from 0.00EUR to 84.00EUR that suggested an upside of 0.15%.
Boasting a price of 73.01EUR, Fresenius (ETR:FRE) traded 0.00% even on the day. With the last stock price close up 0.00% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.05% over the date range. Fresenius has recorded a 50-day average of 41.00EUR and a two hundred day average of 37.00EUR. Volume of trade was down over the average, with 0 shares of FRE changing hands under the typical 34,178
With a total market value of 0 EUR, Fresenius has with a one year low of 0.00EUR and a one year high of 52.00EUR .
Brief Synopsis About Fresenius (ETR:FRE)
Fresenius SE & Co KGaA is a health care company. It operates in the healthcare sector and offers products and services for dialysis, hospitals and outpatient medical care. It focuses on the hospital operations and offers engineering and services for hospitals and other health care facilities. The Company's operating segments include Fresenius Medical Care; Fresenius Kabi; Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment provides dialysis care and dialysis products for patients with chronic kidney failure. The Fresenius Kabi segment is engaged in provision of intravenously administered drugs (IV drugs), infusion therapies, clinical nutrition and outpatient care. The Fresenius Helios segment is a private hospital operator and operates 72 clinics. The Fresenius Vamed segment provides engineering and services for hospitals and other health care facilities internationally.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.